G005540

HPLC Analysis of Dermorphin in Horse Plasma on Ascentis^® Express F5 after SPE with HybridSPE^®

application for HPLC, application for SPE

Propriedades

• técnica(s): HPLC: suitable; solid phase extraction (SPE): suitable
• parâmetros de teste: sample preparation: SPE (Solid Phase Extraction); sample/matrix: horse plasma spiked at 10 μg/mL; SPE tube/cartridge: [TM"HybridSPE"]-Phospholipid Plate, 50mg/96-Well (575656-U); sample addition: 3:1, (1% formic acid in acetonitrile); plasma; column: Ascentis Express F5, 10 cm x 2.1 mm I.D., 2.7 μm particles (53569-U); mobile phase: [A] acetonitrile [B] 20 mM ammonium formate; (90:10, A:B); pH 4.5 with formic acid, after mixing A & B; flow rate: 0.4 mL/min; pressure: 1305 psi (90 bar); column temp.: 35 °C; detector: MS, ESI(+), TIC, m/z 100-1000; injection: 1 μL
• adequação: application for HPLC; application for SPE
• aplicação(ões): forensics and toxicology

Descrição

Nota de análise

Dermorphin is a natural heptapeptide opioid. Because of poor recovery from horse plasma following protein precipitation, alternate methods of extraction are sought. While the HybridSPE protocol successfully removes proteins and phospholipids, dermorphin solubility in plasma remains a limitation. Dermorphin is effectively retained on the pentafluorophenyl phase under aqueous normal phase conditions.

Informações legais

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany